secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001193125-23-293874
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial
--------------------------------------------------------------------------------

- 79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.
- 27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.
- SL-172154 + azacitidine showed acceptable safety; no destructive anemia; most common TEAE was infusion-related reaction.
- Cohorts expanding; Shattuck expects next data update by mid-2024.
- Monotherapy response in R/R AML patient allowed stem cell transplant; patient remains disease-free.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/0001193125-23-293874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/d664766d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-293874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer